Nabil E Boutagy1, Silvia Ravera2, Xenophon Papademetris3, John A Onofrey3, Zhen W Zhuang1, Jing Wu3, Attila Feher1, Mitchel R Stacy1, Brent A French4,5, Brian H Annex4,5, Nancy Carrasco2, Albert J Sinusas1,3. 1. Department of Medicine, Section of Cardiovascular Medicine, Yale Translational Research Imaging Center (N.E.B., Z.W.Z., A.F., M.R.S., A.J.S.), Yale School of Medicine, New Haven, CT. 2. Department of Cellular and Molecular Physiology (S.R., N.C.), Yale School of Medicine, New Haven, CT. 3. Department of Radiology and Biomedical Imaging (X.P., J.A.O., J.W., A.J.S.), Yale School of Medicine, New Haven, CT. 4. Department of Biomedical Engineering (B.A.F., B.H.A.), University of Virginia, Charlottesville. 5. Division of Cardiovascular Medicine, Department of Medicine (B.A.F., B.H.A.), University of Virginia, Charlottesville.
Abstract
BACKGROUND: We propose micro single-photon emission computed tomography/computed tomography imaging of the hNIS (human sodium/iodide symporter) to noninvasively quantify adeno-associated virus 9 (AAV9)-mediated gene expression in a murine model of peripheral artery disease. METHODS: AAV9-hNIS (2×1011 viral genome particles) was injected into nonischemic or ischemic gastrocnemius muscles of C57Bl/6J mice following unilateral hindlimb ischemia ± the α-sialidase NA (neuraminidase). Control nonischemic limbs were injected with phosphate buffered saline or remained noninjected. Twelve mice underwent micro single-photon emission computed tomography/computed tomography imaging after serial injection of pertechnetate (99mTcO4-), a NIS substrate, up to 28 days after AAV9-hNIS injection. Twenty four animals were euthanized at selected times over 1 month for ex vivo validation. Forty-two animals were imaged with 99mTcO4- ± the selective NIS inhibitor perchlorate on day 10, to ascertain specificity of radiotracer uptake. Tissue was harvested for ex vivo validation. A modified version of the U-Net deep learning algorithm was used for image quantification. RESULTS: As quantitated by standardized uptake value, there was a gradual temporal increase in 99mTcO4- uptake in muscles treated with AAV9-hNIS. Hindlimb ischemia, NA, and hindlimb ischemia plus NA increased the magnitude of 99mTcO4- uptake by 4- to 5-fold compared with nonischemic muscle treated with only AAV9-hNIS. Perchlorate treatment significantly reduced 99mTcO4- uptake in AAV9-hNIS-treated muscles, demonstrating uptake specificity. The imaging results correlated well with ex vivo well counting (r2=0.9375; P<0.0001) and immunoblot analysis of NIS protein (r2=0.65; P<0.0001). CONCLUSIONS: Micro single-photon emission computed tomography/computed tomography imaging of hNIS-mediated 99mTcO4- uptake allows for accurate in vivo quantification of AAV9-driven gene expression, which increases under ischemic conditions or neuraminidase desialylation in skeletal muscle.
BACKGROUND: We propose micro single-photon emission computed tomography/computed tomography imaging of the hNIS (humansodium/iodide symporter) to noninvasively quantify adeno-associated virus 9 (AAV9)-mediated gene expression in a murine model of peripheral artery disease. METHODS:AAV9-hNIS (2×1011 viral genome particles) was injected into nonischemic or ischemic gastrocnemius muscles of C57Bl/6J mice following unilateral hindlimb ischemia ± the α-sialidase NA (neuraminidase). Control nonischemic limbs were injected with phosphate buffered saline or remained noninjected. Twelve mice underwent micro single-photon emission computed tomography/computed tomography imaging after serial injection of pertechnetate (99mTcO4-), a NIS substrate, up to 28 days after AAV9-hNIS injection. Twenty four animals were euthanized at selected times over 1 month for ex vivo validation. Forty-two animals were imaged with 99mTcO4- ± the selective NIS inhibitor perchlorate on day 10, to ascertain specificity of radiotracer uptake. Tissue was harvested for ex vivo validation. A modified version of the U-Net deep learning algorithm was used for image quantification. RESULTS: As quantitated by standardized uptake value, there was a gradual temporal increase in 99mTcO4- uptake in muscles treated with AAV9-hNIS. Hindlimb ischemia, NA, and hindlimb ischemia plus NA increased the magnitude of 99mTcO4- uptake by 4- to 5-fold compared with nonischemic muscle treated with only AAV9-hNIS. Perchlorate treatment significantly reduced 99mTcO4- uptake in AAV9-hNIS-treated muscles, demonstrating uptake specificity. The imaging results correlated well with ex vivo well counting (r2=0.9375; P<0.0001) and immunoblot analysis of NIS protein (r2=0.65; P<0.0001). CONCLUSIONS: Micro single-photon emission computed tomography/computed tomography imaging of hNIS-mediated 99mTcO4- uptake allows for accurate in vivo quantification of AAV9-driven gene expression, which increases under ischemic conditions or neuraminidase desialylation in skeletal muscle.
Authors: Annette M Müller; M Iris Hermanns; Carmen Skrzynski; Maya Nesslinger; Klaus-Michael Müller; C James Kirkpatrick Journal: Exp Mol Pathol Date: 2002-06 Impact factor: 3.362
Authors: Jing Hua; Lawrence W Dobrucki; Mehran M Sadeghi; Jiasheng Zhang; Brian N Bourke; Patti Cavaliere; James Song; Conroy Chow; Neda Jahanshad; Niels van Royen; Ivo Buschmann; Joseph A Madri; Marivi Mendizabal; Albert J Sinusas Journal: Circulation Date: 2005-06-13 Impact factor: 29.690
Authors: David S Chang; Hua Su; Gale L Tang; Lucy S Brevetti; Rajabrata Sarkar; Rong Wang; Yuet W Kan; Louis M Messina Journal: Mol Ther Date: 2003-01 Impact factor: 11.454
Authors: Lawrence W Dobrucki; Donald P Dione; Leszek Kalinowski; Donna Dione; Marivi Mendizabal; Jun Yu; Xenophon Papademetris; William C Sessa; Albert J Sinusas Journal: J Nucl Med Date: 2009-07-17 Impact factor: 10.057